Composition for promoting calcium and magnesium absorption, functional milk powder and preparation method and application thereof

By using a specific proportion of breast milk oligosaccharides, astragalus polysaccharides and ginseng powder compositions in functional milk powder, the metabolism of Bifidobacterium brevis is promoted, the problem of low calcium and magnesium absorption efficiency is solved, and the absorption rate of calcium and magnesium is significantly improved.

CN118901804AInactive Publication Date: 2024-11-08YOUBEI NUTRITION TECHNOLOGY (SHENYANG) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411098118.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively promote the absorption of calcium and magnesium, especially by regulating intestinal flora metabolites to improve calcium-binding protein levels and immune responses. Bifidobacter bream metabolic capacity is limited to breast milk oligosaccharides, resulting in calcium and magnesium absorption. Inefficient.

Method used

Provided is a composition comprising a mixture of neutral fucosylated HMOs, neutral nonfucosylated HMOs and acidic sialylated HMOs in a mass ratio of 6:2:2, combined with ginseng powder and astragalus polysaccharide, It is used to prepare functional milk powder, promote the metabolism of Bifidobacterium brevis, improve the production of short-chain fatty acids, and thus enhance the absorption of calcium and magnesium.

Benefits of technology

By adjusting breast milk oligosaccharides of different configurations and adding astragalus polysaccharides and ginseng powder, the metabolic activity of Bifidobacter brevis and the production of short-chain fatty acids was significantly improved, the body's absorption of calcium and magnesium, and the intestinal short-term doublet was improved. Metabolic levels of F. bacterium.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004988575640000051
    Figure BDA0004988575640000051
Patent Text Reader

Abstract

The invention provides a composition for promoting calcium and magnesium absorption, functional milk powder and a preparation method and application thereof, and belongs to the technical field of food. The composition provided by the invention comprises an HMOs mixture, ginseng powder and astragalus polysaccharide, the HMOs mixture is composed of neutral fucosylated HMOs, neutral non-fucosylated HMOs and acidic sialylated HMOs, and the pH value of the HMOs mixture is 7. The mass ratio of the neutral fucosylated HMOs to the neutral non-fucosylated HMOs to the acidic sialylated HMOs is 6: 2: 2. The composition provided by the invention can effectively increase the content of short-chain fatty acids produced by metabolism of bifidobacterium breve, and the formula milk powder prepared by adopting the composition provided by the invention can regulate metabolism of bifidobacterium breve in intestinal tracts and promote absorption of calcium and magnesium elements by organisms.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of food, and in particular relates to a composition for promoting calcium and magnesium absorption, a functional milk powder, and a preparation method and application thereof. Background Art

[0002] Prebiotics can improve calcium absorption and bone health by regulating intestinal flora. Prebiotics are anti-absorbable and can be hydrolyzed and fermented by intestinal microorganisms. When the diet contains sufficient prebiotics, they will selectively stimulate the growth of probiotics, mainly bifidobacteria. They can regulate the body's calcium absorption and bone health by creating a low pH environment in the intestine through bacterial metabolites, regulating the signaling pathways of bone cell metabolism or proliferation, increasing the surface area of ​​intestinal microvilli and increasing the level of calcium-binding protein, upregulating hormone levels, regulating immune responses and improving bone metabolism. The most important bacterial metabolite is short-chain fatty acids (SCFAs).

[0003] Human milk oligosaccharides (HMOs) are a functional prebiotic. The content of human milk oligosaccharides in mature breast milk is 5-15g / L, which is the third largest solid component in breast milk. HMOs are mainly divided into three categories according to their structure: neutral fucosylation, neutral non-fucosylation and acidic sialylation HMOs, among which neutral HMOs account for the largest proportion. Neutral fucosylated HMOs mainly include 2'-fucosyllactose (2'FL) and 3'-fucosyllactose (3'FL), which are composed of fucose and galactose, accounting for 50-80%; neutral non-fucosylated HMOs mainly include lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT); sialylated HMOs mainly include 3'-sialyllactose (3'SL) and 6'-sialyllactose (6'SL), which are composed of sialic acid and lactose, accounting for 10-20%.

[0004] As an important component of intestinal probiotics, bifidobacteria can produce transporters and intracellular / extracellular glycosidases, thereby absorbing and digesting HMOs as the sole carbon source. The mechanism of their HMO metabolism is strain-specific. For example, Bifidobacterium longum subsp. infantis degrades HMOs intracellularly, Bifidobacterium bifidum relies on enzymes attached to the cell membrane to act on HMOs extracellularly, and Bifidobacterium breve has limited ability to degrade HMOs. Improving the ability of Bifidobacterium breve to metabolize HMOs and produce short-chain fatty acids helps the body absorb mineral elements. In addition, β-galactosidase is an important molecular tool in the process of bifidobacterium metabolizing HMOs. When the activity of β-galactosidase increases, the metabolic level of bifidobacteria can be promoted.

[0005] Therefore, the current research hotspot is to provide a functional milk powder that can specifically promote the growth of Bifidobacterium breve and obtain a higher content of short-chain fatty acids by adjusting human milk oligosaccharides of different configurations and compounding ingredients that help improve the function and activity of β-galactosidase. Summary of the invention

[0006] Based on the problems and deficiencies in the prior art, the present invention aims to provide a composition, functional milk powder, and preparation method and application thereof for promoting calcium and magnesium absorption. The composition provided by the present invention comprises an HMOs mixture, ginseng powder and astragalus polysaccharide; the HMOs mixture is composed of neutral fucosylated HMOs, neutral non-fucosylated HMOs and acidic sialylated HMOs; the mass ratio of the neutral fucosylated HMOs, neutral non-fucosylated HMOs and acidic sialylated HMOs is 6:2:2. The composition provided by the present invention can effectively increase the content of short-chain fatty acids produced by the metabolism of Bifidobacterium breve, and the formula milk powder prepared by the composition of the present invention can regulate the metabolism of Bifidobacterium breve in the intestine and promote the body's absorption of calcium and magnesium.

[0007] The technical solution of the present invention is as follows:

[0008] In a first aspect, the present invention provides a composition comprising an HMOs mixture, ginseng powder and astragalus polysaccharide; the HMOs mixture consists of neutral fucosylated HMOs, neutral non-fucosylated HMOs and acidic sialylated HMOs.

[0009] Specifically, the mass ratio of the neutral fucosylated HMOs, the neutral non-fucosylated HMOs and the acidic sialylated HMOs is 6:2:2.

[0010] Preferably, the neutral fucosylated HMOs consist of 2'-fucosyllactose and 3'-fucosyllactose.

[0011] Preferably, the neutral non-fucosylated HMOs consist of lactose-N-tetraose and lactose-N-neotetraose.

[0012] Preferably, the acidic sialylated HMOs consist of 3'-sialyllactose and 6'-sialyllactose.

[0013] Further preferably, the mass ratio of 2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose, and 6'-sialyllactose is 3:3:1:1:1:1.

[0014] Specifically, the composition comprises, by weight, 3.5-7.5 parts of HMOs mixture, 0.35-0.75 parts of ginseng powder and 0.5-1.5 parts of astragalus polysaccharide.

[0015] Preferably, the composition comprises 5 parts of HMOs mixture, 0.5 parts of ginseng powder and 1 part of astragalus polysaccharide by weight.

[0016] In a second aspect, the present invention provides a method for preparing the above-mentioned composition, the preparation method comprising: uniformly mixing the HMOs mixture, ginseng powder and astragalus polysaccharide to obtain the composition.

[0017] In a third aspect, the present invention provides a functional milk powder, comprising the above composition.

[0018] Specifically, the functional milk powder also includes milk powder and composite minerals, and the weight ratio of the milk powder, the composition and the composite minerals is 40-60:6-7:0.25-0.75.

[0019] Preferably, the weight ratio of the milk powder, the composition and the composite minerals is 50:6.5:0.5.

[0020] In a fourth aspect, the present invention provides the use of the above-mentioned composition or functional milk powder in the preparation of products for promoting calcium and magnesium absorption.

[0021] In a fifth aspect, the present invention provides a product for promoting calcium and magnesium absorption, wherein the product comprises the above-mentioned composition or functional milk powder.

[0022] Specifically, the products include functional foods, health products or medicines.

[0023] Preferably, the product is a functional food.

[0024] In a sixth aspect, the present invention provides a functional food for promoting calcium and magnesium absorption, wherein the functional food comprises the above-mentioned composition or functional milk powder.

[0025] Specifically, the functional food also includes nutritional additives that are nutritionally acceptable.

[0026] Preferably, the nutritional additives include one or more of dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0027] Specifically, the dosage form of the functional food includes a liquid dosage form, a solid dosage form or a semi-solid dosage form.

[0028] Preferably, the functional food includes candy flakes, soy milk, yogurt, canned food, biscuits, chocolate, cakes, cream, cheese, milk powder, formula milk powder, ice cream, jam, puree, candied fruit, preserved fruit, bread, egg rolls, protein drinks, solid drinks, lactic acid bacteria drinks, plant protein drinks, carbonated drinks, coffee or puffed food.

[0029] In a seventh aspect, the present invention provides a health product for promoting calcium and magnesium absorption, wherein the health product comprises the above-mentioned composition or functional milk powder.

[0030] Specifically, the health care product also includes nutritional additives that are nutritionally acceptable.

[0031] Preferably, the nutritional additives include one or more of dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0032] Specifically, the dosage forms of the health care products include tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids or drops.

[0033] In an eighth aspect, the present invention provides a medicine for promoting calcium and magnesium absorption, wherein the medicine comprises the above-mentioned composition or functional milk powder.

[0034] Specifically, the medicine further includes one or more physiologically acceptable auxiliary materials or pharmaceutically acceptable excipients.

[0035] Preferably, the physiologically acceptable excipients include, but are not limited to, erythritol, D-mannitol, fumaric acid, glycerol, pectin, potassium alginate, sodium alginate, talc, sodium pyrophosphate, polydextrose, carrageenan, sodium ascorbate, ascorbyl palmitate, L-malic acid, L(+) tartaric acid, maltitol, gelatin, xylitol, citric acid, potassium citrate, sodium citrate, citric acid fatty acid glyceride, agar, lactic acid, sodium lactate, sorbic acid and its potassium salt, sorbitol, acid red, calcium carbonate, sodium carbonate, sodium bicarbonate, beet red, vitamin C, vitamin E, oxidized starch, ethanol, sodium acetate, stearic acid, calcium stearate, magnesium stearate or dextrin.

[0036] Preferably, the pharmaceutically acceptable excipients include, but are not limited to, solvents, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, binders, lubricants, dispersants, suspending agents, isotonic agents, thickeners, emulsifiers, preservatives, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, flavoring agents, sweeteners, ion exchangers, release agents, coating agents, flavoring agents or antioxidants.

[0037] The beneficial effects of the present invention are:

[0038] (1) The composition provided by the present invention contains human milk oligosaccharides of different configurations, which can promote the growth and metabolism of Bifidobacterium breve under specific conditions. The compounding of astragalus polysaccharide and ginseng powder can promote the activity and function of β-galactosidase necessary for bifidobacterium to metabolize HMOs. The combination of the above-mentioned ingredients can effectively increase the content of short-chain fatty acids produced by the metabolism of Bifidobacterium breve, thereby promoting the body's absorption of calcium and magnesium.

[0039] (2) The functional milk powder prepared from the composition provided by the present invention can regulate the metabolism of Bifidobacterium breve in the intestine and promote the body's absorption of calcium and magnesium. DETAILED DESCRIPTION

[0040] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0041] The material information used in the present invention is shown in Table 1:

[0042] Table 1 Experimental materials

[0043]

[0044] Example 1 Preparation of experimental materials

[0045] 1. Preparation of HMOs mixture:

[0046] 2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose, and 6'-sialyllactose are uniformly mixed according to a weight ratio to obtain a HMOs mixture.

[0047] In certain embodiments, the weight ratio of 2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose, and 6'-sialyllactose is 3:3:1:1:1:1; in certain embodiments, the weight ratio of 2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose, and 6'-sialyllactose is 1:1:1:1:1:1:1.

[0048] 2. Preparation of ginseng powder:

[0049] Grind the ginseng into powder to make ginseng powder, set aside.

[0050] 3. MRS medium:

[0051] Peptone 10.0g; beef extract 10.0g; yeast powder 5.0g; glucose 20.0g; sodium acetate 5.0g; diammonium hydrogen citrate 2.0g; Tween-80 1.0ml; dipotassium hydrogen phosphate 2.0g; magnesium sulfate heptahydrate 0.2g; manganese sulfate heptahydrate 0.05g; add distilled water to make up to 1.0L, sterilize at 115℃ for 30 minutes and set aside.

[0052] Example 2 Strain culture experiment

[0053] 1. Experimental Grouping

[0054] Control group: MRS medium

[0055] Experimental group 1: MRS medium containing 1% HMOs mixture (2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose, and 6'-sialyllactose in a weight ratio of 3:3:1:1:1:1), 0.1% ginseng powder, and 0.2% astragalus polysaccharide.

[0056] Experimental group 2: MRS medium containing 1% HMOs mixture (2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose, and 6'-sialyllactose in a weight ratio of 1:1:1:1:1:1), 0.1% ginseng powder, and 0.2% astragalus polysaccharide.

[0057] Experimental group 3: MRS medium containing 0.1% ginseng powder and 0.2% astragalus polysaccharide.

[0058] Experimental group 4: MRS medium containing 1% HMOs mixture (2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose, and 6'-sialyllactose in a weight ratio of 3:3:1:1:1:1), 0.2% astragalus polysaccharide.

[0059] Experimental group 5: MRS medium containing 1% HMOs mixture (2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose, and 6'-sialyllactose in a weight ratio of 3:3:1:1:1:1) and 0.1% ginseng powder.

[0060] Experimental group 6: MRS medium containing 1% HMOs mixture (2'-fucosyllactose, 3'-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, 3'-sialyllactose, 6'-sialyllactose in a weight ratio of 3:3:1:1:1:1).

[0061] 2. Strain culture

[0062] Take 10 μL (1×10 6 CFU / mL), and inoculated into 10 mL of culture medium of different groups respectively. After anaerobic culture at 37°C for 24 h, the fermentation liquid was stored in a sterilized Eppendorf tube for later use.

[0063] 3. Determination of fatty acids

[0064] The external standard method was used to determine the short-chain fatty acids (acetic acid, propionic acid, butyric acid, and valeric acid). Take 2 mL of the fermentation broth from each group, centrifuge at 4°C and 10000g for 5 min, take 1 mL of the supernatant and place it in a 2 mL centrifuge tube, add 5 μL of 0.5 mol / L sulfuric acid solution and shake and mix, take 1 mL of ethyl acetate and shake and mix it, centrifuge at 4°C and 10000g for 10 min, take the upper organic phase and filter it through a 0.22 μm filter membrane and place it in a sample bottle, and detect the content of short-chain fatty acids by gas chromatography. The standard product was treated in the same way as the fermentation broth, with the concentration of the standard solution as the horizontal axis and the peak area as the vertical axis, and regression analysis was performed to draw a standard curve to calculate the content of short-chain fatty acids in the sample.

[0065] The measurement results are shown in Table 2, which show that the culture medium of the experimental group 1 provided by the present invention has the highest short-chain fatty acid content.

[0066] Table 2 Short chain fatty acid content

[0067] Acetic acid mmol / L Propionic acid mmol / L Butyrate mmol / L Valeric acid mmol / L Control group 21.328 10.197 4.108 5.086 Experimental Group 1 29.884 11.239 5.489 5.361 Experimental Group 2 26.575 10.913 4.972 5.010 Experimental Group 3 23.702 10.291 4.343 5.223 Experimental Group 4 24.321 10.345 4.813 5.246 Experimental Group 5 24.487 10.314 4.652 5.125 Experimental Group 6 25.201 10.513 4.646 5.175

[0068] Example 3 Preparation of milk powder for promoting calcium and magnesium absorption

[0069] 1. Preparation of HMOs mixture

[0070] 2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose and 6'-sialyllactose were uniformly mixed in a weight ratio of 3:3:1:1:1:1 to prepare a HMOs mixture.

[0071] 2. Preparation of milk powder

[0072] 50g of milk powder, 5g of HMOs mixture, 0.5g of ginseng powder, 1g of astragalus polysaccharide and 0.5g of complex minerals are compounded to obtain milk powder with the function of promoting calcium and magnesium absorption.

[0073] Comparative Example 1 Preparation of milk powder for promoting calcium and magnesium absorption

[0074] The difference between Comparative Example 1 and Example 1 is only that: "1. Preparation of HMOs mixture" is different. The specific preparation method is:

[0075] 2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose and 6'-sialyllactose are uniformly mixed in a weight ratio of 2'-fucosyllactose: 3'-fucosyllactose: lactose-N-tetraose: lactose-N-neotetraose: 3'-sialyllactose: 6'-sialyllactose = 1:1:1:1:1:1 to prepare a HMOs mixture.

[0076] Comparative Example 2 Preparation of milk powder for promoting calcium and magnesium absorption

[0077] 50g of milk powder, 0.5g of ginseng powder, 1g of astragalus polysaccharide and 0.5g of complex minerals are compounded to obtain milk powder with the function of promoting calcium and magnesium absorption.

[0078] Comparative Example 3 Preparation of milk powder for promoting calcium and magnesium absorption

[0079] The difference between Comparative Example 3 and Example 3 is only that: "2. Preparation of milk powder" is different.

[0080] 50g of milk powder, 5g of HMOs mixture, 1g of astragalus polysaccharide and 0.5g of complex minerals are compounded to obtain milk powder with the function of promoting calcium and magnesium absorption.

[0081] Comparative Example 4 Preparation of milk powder for promoting calcium and magnesium absorption

[0082] The difference between Comparative Example 4 and Example 3 is only that: "2. Preparation of milk powder" is different.

[0083] 50g of milk powder, 5g of HMOs mixture, 0.5g of ginseng powder and 0.5g of complex minerals are compounded to obtain milk powder with the function of promoting calcium and magnesium absorption.

[0084] Comparative Example 5 Preparation of milk powder for promoting calcium and magnesium absorption

[0085] The difference between Comparative Example 5 and Example 3 is only that: "2. Preparation of milk powder" is different.

[0086] 50g of milk powder, 5g of HMOs mixture and 0.5g of complex minerals are compounded to obtain milk powder with the function of promoting calcium and magnesium absorption.

[0087] Experimental Example 1 Determination of calcium and magnesium absorption rate

[0088] 1. Grouping and Dosing

[0089] The milk powders prepared in Example 3 and Comparative Examples 1-5 were dissolved in 1 mL of physiological saline before use and used for intragastric administration.

[0090] 35 SPF male Wistar rats, weighing 300 ± 3g, were randomly divided into 7 groups after adaptive feeding for one week, 5 rats in each group, namely, the control group, the example 3 group, and the comparative example 1-5 group. The experimental example 3 group and the comparative example 1-5 group were gavaged with the milk powder of the example 3 or the comparative example 1-5, respectively, and the gavage dosage was 2g / kg, and the product was mixed in 1mL of normal saline, and the gavage was administered once a day, and the experimental period was 13 weeks. The control group compounded 50g of milk powder and 0.5g of composite minerals, dissolved in 1mL of normal saline, and gavaged the mice as a control.

[0091] 2. Calcium metabolism test

[0092] At the end of the 13th week, the food intake for 3 days was recorded, feces were collected for 72 hours, the calcium content in the feed and feces was determined, and the apparent calcium absorption rate was calculated; apparent calcium absorption rate (%) = (calcium content in feed + calcium content by oral administration - calcium content in feces) ÷ (calcium content in feed + calcium content by oral administration) × 100%.

[0093] 3. Magnesium metabolism test

[0094] At the end of the 13th week, the food intake for 3 days was recorded, feces were collected for 72 hours, the magnesium content in the feed and feces was determined, and the apparent absorption rate of magnesium was calculated; apparent absorption rate of magnesium (%) = (magnesium content in feed + magnesium content by oral administration - magnesium content in feces) ÷ (magnesium content in feed + magnesium content by oral administration) × 100%.

[0095] The results of the determination of the apparent absorption rate of calcium and magnesium in rats are shown in Table 3. The determination results show that the milk powder prepared in Example 3 provided by the present invention has the most obvious effect of improving the absorption rate of calcium and magnesium in rats.

[0096] Table 3 Calcium and magnesium absorption rate

[0097] Group Apparent calcium absorption rate in rats % Apparent absorption rate of magnesium in rats % Control group 49.7 68.3 Example 3 98.2 91.7 Comparative Example 1 92.4 87.9 Comparative Example 2 71.3 79.6 Comparative Example 3 80.3 81.3 Comparative Example 4 88.9 85.0 Comparative Example 5 82.8 82.5

[0098] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.

Claims

1. A composition, It is characterized in that The composition comprises a HMOs mixture, ginseng powder and astragalus polysaccharide; The HMOs mixture is composed of neutral fucosylated HMOs, neutral non-fucosylated HMOs and acidic sialylated HMOs; the mass ratio of the neutral fucosylated HMOs, neutral non-fucosylated HMOs and acidic sialylated HMOs is 6:2:2; The neutral fucosylated HMOs are composed of 2'-fucosyllactose and 3'-fucosyllactose; The neutral non-fucosylated HMOs are composed of lactose-N-tetraose and lactose-N-neotetraose; The acidic sialylated HMOs are composed of 3'-sialyllactose and 6'-sialyllactose.

2. The composition according to claim 1, It is characterized in that The composition comprises 3.5-7.5 parts of HMOs mixture, 0.35-0.75 parts of ginseng powder and 0.5-1.5 parts of astragalus polysaccharide by weight.

3. The composition according to claim 2, It is characterized in that The composition comprises 5 parts of HMOs mixture, 0.5 parts of ginseng powder and 1 part of astragalus polysaccharide by weight.

4. The composition according to claim 1, It is characterized in that The mass ratio of 2'-fucosyllactose, 3'-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3'-sialyllactose and 6'-sialyllactose is 3:3:1:1:1:

1.

5. A method for preparing the composition according to any one of claims 1 to 4, It is characterized in that The preparation method comprises: uniformly mixing the HMOs mixture, ginseng powder and astragalus polysaccharide to obtain the composition.

6. A functional milk powder, It is characterized in that The functional milk powder comprises the composition according to any one of claims 1 to 4.

7. The functional milk powder according to claim 6, It is characterized in that The functional milk powder also includes milk powder and composite minerals. The weight ratio of the milk powder, the composition and the composite minerals is 40-60:6-7:0.25-0.

75.

8. The functional milk powder according to claim 7, It is characterized in that The weight ratio of the milk powder, the composition and the composite minerals is 50:6.5:0.

5.

9. Use of the composition according to any one of claims 1 to 4 or the functional milk powder according to any one of claims 6 to 8 in the preparation of products promoting calcium and magnesium absorption.

10. A product that promotes calcium and magnesium absorption, It is characterized in that The food contains the composition according to any one of claims 1 to 4 or the functional milk powder according to any one of claims 6 to 8.